共查询到20条相似文献,搜索用时 0 毫秒
1.
Aldosterone as a cardiovascular risk hormone 总被引:4,自引:0,他引:4
The pathophysiological role of aldosterone in the development of cardiovascular disease has long been considered to be due its potent volume expansion/hypertensive effect mainly via mineralocorticoid receptor (MR) expressed in renal tubular epithelial cells. However, recent accumulating lines of evidence from clinical and experimental studies have suggested that direct cardiovascular effect of aldosterone contributes to the development of cardiovascular injury via MRs in non-epithelial tissue. A series of recent clinical studies have revealed that patients with primary aldosteronism have higher incidence of cardiovascular and renal complications than those with essential hypertension, and that aldosterone antagonism has cardiovascular protective effect in patients with heart failure independent from blood pressure. Numerous experimental studies have shown that both inflammation and oxidative stress play an initial and key role in the development of aldosterone-induced cardiovascular injury via non-epithelial MR activation. In this review, we discuss recent research progress in aldosterone and MR effects, with special emphasis on the pathophysiological role of aldosterone in cardiovascular diseases and the possible molecular mechanism(s) of cardiovascular injury by non-epithelial MR activation. 相似文献
2.
Aldosterone as a cardiovascular risk factor. 总被引:5,自引:0,他引:5
GianPaolo Rossi Marco Boscaro Vanessa Ronconi John W Funder 《Trends in Endocrinology and Metabolism》2005,16(3):104-107
Aldosterone exerts cardiovascular effects by influencing epithelial fluid and electrolyte excretion, and thus blood volume and pressure. Mineralocorticoid receptors (MR) are found in epithelial and non-epithelial tissues (vessel walls, heart, brain), with high affinity for aldosterone and physiological glucocorticoids cortisol and corticosterone. MR blockade by spironolactone or eplerenone favorably affects cardiovascular outcomes. In some situations (primary aldosteronism, experimental mineralocorticoid administration) activation of cardiovascular MR reflects aldosterone levels inappropriate for salt status. In others (heart failure, essential hypertension) aldosterone and Na(+) status are often normal pretreatment; cardiovascular MR may thus be activated by normal glucocorticoid levels after tissue damage and reactive oxygen species generation. Therefore, although unilateral adrenalectomy is preferred therapy for unilateral aldosterone-producing adenoma or hyperplasia, MR blockade may be useful in cardiovascular diseases where aldosterone levels are normal. 相似文献
3.
Aldosterone blockade in cardiovascular disease 总被引:3,自引:0,他引:3
Struthers AD 《Heart (British Cardiac Society)》2004,90(10):1229-1234
4.
Calhoun DA 《Circulation》2006,114(24):2572-2574
5.
The renin-angiotensin-aldosterone system plays a central role in the development of hypertension and the progression of end-organ damage. Although angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists can initially suppress plasma aldosterone, it is now well established that aldosterone escape may occur, whereby aldosterone levels return to or exceed baseline levels. The classic effects of aldosterone relate mainly to its action on epithelial cells to regulate water and electrolyte balance. However, blood pressure reduction or fluid loss could not account for the results of the Randomized Aldactone Evaluation Study, which showed that a low dose of spironolactone in addition to conventional therapy could decrease the overall risk of mortality by 30% among patients with severe congestive heart failure. The action of aldosterone at nonepithelial sites in the brain, heart, and vasculature is consistent with the presence of mineralocorticoid receptors in these tissues. Aldosterone has a number of deleterious effects on the cardiovascular system, including myocardial necrosis and fibrosis, vascular stiffening and injury, reduced fibrinolysis, endothelial dysfunction, catecholamine release, and production of cardiac arrhythmias. Several studies have now shown vascular and target-organ protective effects of aldosterone receptor antagonism in the absence of significant blood pressure lowering, consistent with a major role for endogenous mineralocorticoids as mediators of cardiovascular injury. The advent of selective aldosterone receptor antagonists such as eplerenone should prove of great therapeutic value in the prevention of cardiovascular disease and associated end-organ damage. 相似文献
6.
7.
Sarzani R Salvi F Dessì-Fulgheri P Catalini R Mazzara D Cola G Siragusa N Spagnolo D Ercolani P Gesuita R Carle F Rappelli A 《Journal of human hypertension》2003,17(12):859-864
The C(-344)T promoter polymorphism of the human aldosterone synthase (CYP11B2) gene has been associated with hypertension and cardiac hypertrophy, but there were contrasting data. We analysed the genotype/phenotype associations between this polymorphism and cardiovascular variables in a young adult population, where interactions among genes, gene-environment, and acquired ageing-related organ damage are reduced. Anthropometric measurements, blood pressure, heart rate, left ventricular variables (by echocardiography), and carotid artery wall intimal-media thickness (by high-resolution sonography and digitalized morphometry) were taken in 420 white Caucasian students (mean age 23.5 years, s.d. 2.5 years). CYP11B2 alleles were detected by genomic polymerase chain reaction followed by digestion. Taking into account the three possible models of inheritance, we found no differences in the considered variables, except for an independent effect of the C(-344) allele on SBP in males (TT 125.6 (1.6), TC 128.4 (1.2) and CC 130.5 (2.2), mmHg, media (ES), P=0.03), and on interventricular septum thickness in diastole in females (CC 6.98 (0.12) vs TT 6.87 (0.09) and TC 6.87 (0.07), mmHg, P<0.01), in the codominant model. In conclusion, the CYP11B2 C(-344)T polymorphism appears to have a slight role in the cardiovascular phenotype of young healthy adults, even if these genotype/phenotype relationships might change with ageing. 相似文献
8.
Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy 总被引:2,自引:0,他引:2
Ambroisine ML Milliez P Nehme J Pasquier AL De Angelis N Mansier P Swynghedauw B Delcayre C 《Diabetes & metabolism》2004,30(4):311-318
Cells in the cortical collecting duct of distal nephron have been considered for a long time as the unique cellular targets of aldosterone. However, it is now clear that other cell types in non-epithelial tissues are also potential targets for aldosterone. The functions that this hormone controls in non-epithelial tissues are still a matter of debate. Clinical and experimental studies have established that aldosterone plays a major role in the pathophysiology of cardiovascular and renal diseases. The aldosterone receptor antagonists spironolactone and eplerenone have demonstrated specific effects not related to their hypotensive properties in hypertension or cardiac diseases. It appears that a key action of these molecules is related to prevention or treatment of end-organ damage. The latter fact, and the recognition of aldosterone escape on long-term treatment of heart failure, diabetic nephropathy and some forms of hypertension with ACE inhibitors, justify the clinical use of aldosterone receptor antagonists provided that kaliemia is controlled. Experimental studies have allowed to draw a still incomplete but comprehensive scheme of aldosterone cardiovascular actions in pathological conditions. When elevated, aldosterone has deleterious effects in blood vessels, in the heart and in kidney, which are secondary to the induction of inflammatory and oxidative processes and necrosis, that induce the increased synthesis of extracellular matrix proteins. 相似文献
9.
10.
Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease 总被引:7,自引:0,他引:7
Bravo EL 《Current hypertension reports》2003,5(2):122-125
Recent preclinical and clinical studies indicate that aldosterone, independent of angiotensin II and elevated blood pressure,
may play a role in health and disease. In addition to its role in fluid and electrolyte balance and circulatory homeostasis,
more recent studies have identified aldosterone as a critical mediator of vascular damage. In animal studies, aldosterone
is implicated in cardiac and vascular fibrosis, renal disease, and cerebrovascular damage. These lesions are prevented by
specific aldosterone receptor blockade. In clinical studies, aldosterone receptor antagonism is associated with decreased
hospitalization, symptomatology, and mortality, and improvement of endothelial dysfunction in patients with chronic heart
failure. A better understanding of aldosterone’s actions in nonepithelial tissues should pave the way to better protection
of organs at risk such as the kidneys, heart, and brain. 相似文献
11.
Tomaschitz A Ritz E Pieske B Fahrleitner-Pammer A Kienreich K Horina JH Drechsler C März W Ofner M Pieber TR Pilz S 《Cardiovascular research》2012,94(1):10-19
Animal and human studies support a clinically relevant interaction between aldosterone and parathyroid hormone (PTH) levels and suggest an impact of the interaction on cardiovascular (CV) health. This review focuses on mechanisms behind the bidirectional interactions between aldosterone and PTH and their potential impact on the CV system. There is evidence that PTH increases the secretion of aldosterone from the adrenals directly as well as indirectly by activating the renin-angiotensin system. Upregulation of aldosterone synthesis might contribute to the higher risk of arterial hypertension and of CV damage in patients with primary hyperparathyroidism. Furthermore, parathyroidectomy is followed by decreased blood pressure levels and reduced CV morbidity as well as lower renin and aldosterone levels. In chronic heart failure, the aldosterone activity is inappropriately elevated, causing salt retention; it has been argued that the resulting calcium wasting causes secondary hyperparathyroidism. The ensuing intracellular calcium overload and oxidative stress, caused by PTH and amplified by the relative aldosterone excess, may increase the risk of CV events. In the setting of primary aldosteronism, renal and faecal calcium loss triggers increased PTH secretion which in turn aggravates aldosterone secretion and CV damage. This sequence explains why adrenalectomy and blockade of the mineralocorticoid receptor tend to decrease PTH levels in patients with primary aldosteronism. In view of the reciprocal interaction between aldosterone and PTH and the potentially ensuing CV damage, studies are urgently needed to evaluate diagnostic and therapeutic strategies addressing the interaction between the two hormones. 相似文献
12.
13.
Andreas Tomaschitz Eberhard Ritz Burkert Pieske Jutta Rus-Machan Katharina Kienreich Nicolas Verheyen Martin Gaksch Martin Grübler Astrid Fahrleitner-Pammer Peter Mrak Hermann Toplak Elisabeth Kraigher-Krainer Winfried März Stefan Pilz 《Metabolism: clinical and experimental》2014
Inappropriate aldosterone and parathyroid hormone (PTH) secretion is strongly linked with development and progression of cardiovascular (CV) disease. Accumulating evidence suggests a bidirectional interplay between parathyroid hormone and aldosterone. This interaction may lead to a disproportionally increased risk of CV damage, metabolic and bone diseases. 相似文献
14.
Aldosterone: A risk factor for vascular disease 总被引:8,自引:0,他引:8
Blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor
antagonists has resulted in beneficial effects in essential hypertensive patients. However, occurrence of cardiovascular events
has not been appropriately controlled beyond a certain percentage. One reason could be the effects of aldosterone, the final
component of the system. The aldosterone escape phenomenon could explain undesirable outcomes observed in hypertensive patients
even under treatment with ACE inhibitors or angiotensin antagonists. Aldosterone has direct effects on the vasculature and
has been associated with vascular smooth muscle cell hypertrophy, endothelial dysfunction, cardiac fibrosis, proteinuria,
and renal vascular injury. Animal models and clinical trials have proven the benefit of aldosterone receptor antagonism. With
increased recognition of the prevalence of hyperaldosteronism in patients thought to have "essential" hypertension, the use
of drugs that block aldosterone action may become more widespread and protect the vasculature from the deleterious effects
of aldosterone. 相似文献
15.
16.
Rosiglitazone and cardiovascular risk 总被引:1,自引:0,他引:1
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a
43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In
this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone
and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care
providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease
for diabetic patients taking rosiglitazone are inconclusive. 相似文献
17.
18.
Aukrust P Halvorsen B Yndestad A Ueland T Øie E Otterdal K Gullestad L Damås JK 《Arteriosclerosis, thrombosis, and vascular biology》2008,28(11):1909-1919
Based on the importance of inflammation in atherogenesis, recent work has focused on whether plasma markers of inflammation can noninvasively diagnose and prognosticate atherosclerotic disorders. Although several studies support an important pathogenic role of chemokines in atherosclerosis, potentially representing attractive therapeutic targets in atherosclerotic disorders, this does not necessarily mean that chemokines are suitable parameters for risk prediction. In fact, the ability to reflect upstream inflammatory activity, stable levels in individuals, and high stability of the actual protein (eg, long half-life and negligible circadian variation) are additional important criteria for an ideal biomarker in cardiovascular disease. Although plasma/serum levels of certain chemokines (eg, interleukin- 8/CXCL8 and monocyte chemoattractant protein-1/CCL2) have shown to be predictive for future cardiac events in some studies, their role as clinical biomarkers is unclear, and their ability to predict subclinical atherosclerosis has been disappointing. Further prospective studies, including a larger number of patients, are needed to make any firm conclusion. Based on the participation of several chemokines in atherogenesis, it is possible that in the future, combined measurements of multiple chemokines could reveal as a "signature of disease" that can serve as a highly accurate method to assess for the presence of atherosclerotic disease. 相似文献
19.
Cardiovascular diseases represent, today, the principal cause of mortality in the general population, especially in subjects with type 2 diabetes mellitus. In these patients the risk of death from cardiovascular diseases is equal to that of non-diabetic subjects with a previous episode of myocardial infarction. Many factors concur to determine such high risk. Hyperglycaemia contributes to the increase in morbidity and cardiovascular mortality associated with diabetes mellitus. Hyperglycaemia acts as a multiplier of cardiovascular risk due to frequent association of multiple risk factors in diabetic patients. Therefore, effective treatment requires a more complete assessment of quantitative and qualitative aspects of glycemic control as well as all components of the diabetic syndrome or, more commonly, metabolic syndrome. 相似文献
20.